One Of The Five Cyclos Is Five-membered And Includes Ring Chalcogen (e.g., Codeine, Morphine, Etc.) Patents (Class 514/282)
  • INTRANASAL NALTREXONE
    Publication number: 20140249172
    Abstract: A stable transmucosal composition consisting essentially of naltrexone hydrochloride in water is provided. The composition is surprisingly stable at room temperature and can be used for simple, rapid and effective opioid overdose rescue.
    Type: Application
    Filed: May 16, 2014
    Publication date: September 4, 2014
    Applicant: 3B Pharmaceuticals, Inc.
    Inventors: Darby C. Brown, Jason Montgomery, Beau Gertz
  • ABUSE RESISTANT FORMS OF EXTENDED RELEASE MORPHINE, METHOD OF USE AND METHOD OF MAKING
    Publication number: 20140248344
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Application
    Filed: May 9, 2014
    Publication date: September 4, 2014
    Applicant: lnspirion Delivery Technologies, LLC
    Inventors: Manish S. SHAH, Ray J. DiFalco
  • ABUSE RESISTANT FORMS OF EXTENDED RELEASE MORPHINE, METHOD OF USE AND METHOD OF MAKING
    Publication number: 20140248343
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Application
    Filed: May 9, 2014
    Publication date: September 4, 2014
    Applicant: Inspirion Delivery Technologies, LLC
    Inventors: Manish S. SHAH, Ray J. DiFalco
  • MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION
    Publication number: 20140248346
    Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a pharmaceutically active agent that can be the same or different from the pharmaceutically active agent in the microparticles. The composition further comprises a superabsorbent material disposed within the first layer, the second layer, or both the first layer and the second layer. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the composition.
    Type: Application
    Filed: March 3, 2014
    Publication date: September 4, 2014
    Applicants: PALADIN LABS INC., PALADIN LABS EUROPE LIMITED, PALADIN LABS (BARBADOS) INC.
    Inventors: Miloud Rahmouni, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Ali Bichara
  • Opioid agonist/opioid antagonist/acetaminophen combinations
    Patent number: 8822487
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: September 2, 2014
    Assignee: Purdue Pharma L.P.
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Non-abusable pharmaceutical composition comprising opioids
    Patent number: 8821914
    Abstract: There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: September 2, 2014
    Assignee: Orexo AB
    Inventor: Anders Pettersson
  • 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
    Patent number: 8822450
    Abstract: Compounds of Formula (I), their preparation and use in preventing or treating bacterial infection is disclosed.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: September 2, 2014
    Assignee: Wockhardt Ltd.
    Inventors: Mahesh Vithalbhai Patel, Prasad Keshav Deshpande, Satish Bhawsar, Sachin Bhagwat, Mohammed Alam Jafri, Amit Mishra, Laxmikant Pavase, Sunil Gupta, Rajesh Kale, Sanjeev Joshi
  • Abuse deterrent compositions and methods of making same
    Patent number: 8822489
    Abstract: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: September 2, 2014
    Assignee: Acura Pharmaceuticals
    Inventors: Vijai Kumar, David Dixon, Divya Tewari, Dilip B. Wadgaonkar
  • Compositions of buprenorphine and ? antagonists
    Patent number: 8822488
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUB ) BC 30 ] [ C max ( ANTAGONIST ) IC 30 ] .
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: September 2, 2014
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Peripheral opioid receptor antagonists and uses thereof
    Patent number: 8822490
    Abstract: The present invention provides a compound of formula I: wherein X?, R1, and R2 are as defined herein, and compositions thereof.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: September 2, 2014
    Assignee: Wyeth LLC
    Inventors: Nataliya Bazhina, George Joseph Donato, III, Steven R. Fabian, John Lokhnauth, Sreenivasulu Megati, Charles Melucci, Christian Ofslager, Niketa Patel, Galen Radebaugh, Syed M. Shah, Jan Szeliga, Huyi Zhang, Tianmin Zhu
  • METHODS AND COMPOSITIONS FOR TREATING ANXIETY DISORDERS OR SYMPTOMS THEREOF
    Publication number: 20140243363
    Abstract: The present invention relates to methods and compositions for reducing distress dysfunction, including emotional and physical distress. The invention entails co-administration of at least one Receptor Switcher and at least one Endorphin Enhancer. Additionally, at least one Synergistic Enhance and/or at least one Exogenous Opioid are also administered to enhance or prolong the therapeutic effects.
    Type: Application
    Filed: May 1, 2014
    Publication date: August 28, 2014
    Applicant: PONDERA BIOTECHNOLOGIES INC.
    Inventors: Steven Crain, William E. Crain, Stanley M. Crain, Michael Crain
  • Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
    Patent number: 8816083
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydromorphone (4,5-?-epoxy-3-hydroxy-17-methyl morphinan-6-one) to form novel prodrugs/compositions of hydromorphone. The hydromorphone prodrugs of the present technology have decreased side effects and decreased potential for abuse compared to unconjugated hydromorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: August 26, 2014
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Compositions and methods for increasing insulin sensitivity
    Patent number: 8815889
    Abstract: Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: August 26, 2014
    Assignee: Orexigen Therapeutics, Inc.
    Inventors: Michael A. Cowley, Anthony A. McKinney, Gary Tollefson
  • STABLE PHARMACEUTICAL FORMULATIONS OF METHYLNALTREXONE
    Publication number: 20140235664
    Abstract: Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided.
    Type: Application
    Filed: September 27, 2013
    Publication date: August 21, 2014
    Applicant: Progenics Pharmaceuticals, Inc.
    Inventors: Suketu P. Sanghvi, Thomas A. Boyd
  • COMBINATION OF PILOCARPIN AND METHIMAZOL FOR TREATING CHARCOT-MARIETOOTH DISEASE AND RELATED DISORDERS
    Publication number: 20140235599
    Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related peripheral neuropathies. More particularly, the invention relates to combined therapies for treating said disease by affecting simultaneously muscarinic receptor signalling and thyroid hormone pathway in a subject.
    Type: Application
    Filed: May 5, 2014
    Publication date: August 21, 2014
    Inventors: DANIEL COHEN, ILYA CHUMAKOV, SERGUEI NABIROCHKIN, OXANA GUERASSIMENKO
  • Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment
    Patent number: 8808737
    Abstract: The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician that the bioavailability of oxymorphone is increased in patients with renal impairment.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: August 19, 2014
    Assignee: Endo Pharmaceuticals Inc.
    Inventor: Harry Ahdieh
  • DRY POWDER COMPOUND FORMULATIONS AND USES THEREOF
    Publication number: 20140228389
    Abstract: The present invention provides lyophilized formulations comprising methylnaltrexone, and processes for preparation of provided formulations. Additionally provided are compositions and products containing the methylnaltrexone formulation, as well as methods for producing formulations, compositions and products. Provided formulations as well as compositions and products containing methylnaltrexone formulations are useful for preventing, treating delaying, diminishing or reducing the severity and/or incidence of side effects resulting from administration of analgesic opioids.
    Type: Application
    Filed: September 16, 2013
    Publication date: August 14, 2014
    Applicant: WYETH, LLC
    Inventors: Syed M. Shah, Christian Ofslager
  • Pharmaceutical Formulation Containing Gelling Agent
    Publication number: 20140228390
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: April 17, 2014
    Publication date: August 14, 2014
    Applicants: Purdue Pharma L.P., The P.F. Laboratories, Inc., PURDUE PHARMACEUTICALS L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Domperidone at a low daily dose for use in the treatment or prevention of a disease associated with an alteration of the immune response
    Patent number: 8802691
    Abstract: The invention relates to the use of domperidone or a pharmaceutically acceptable salt thereof at low doses to prevent and/or treat a disease associated with an alteration of the immune response such as Leishmaniosis.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: August 12, 2014
    Assignee: Laboratorios del Dr. Esteve, S.A.
    Inventors: David Sabate Elias, Josep M. Homedes Beguer, Pablo Gomez Ochoa
  • Pharmaceutical compositions with attenuated release of phenolic opioids
    Patent number: 8802681
    Abstract: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: August 12, 2014
    Assignee: Signature Therapeutics, Inc.
    Inventors: Thomas E. Jenkins, Julie D. Seroogy, Jonathan W. Wray
  • REDUCTION OF OPIOID BLOOD FLUCTUATIONS
    Publication number: 20140220127
    Abstract: The present invention relates to the use of a sustained release matrix containing at least one opioid for producing a solid oral formulation in table form suitable for reducing blood concentration fluctuations of said opioid.
    Type: Application
    Filed: April 11, 2014
    Publication date: August 7, 2014
    Applicant: ETHYPHARM
    Inventors: Catherine HERRY, Maryline BOYER, Francoise VAUZELLE-KERVROEDAN, Pascal OURY
  • ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED RELEASE
    Publication number: 20140220126
    Abstract: The present disclosure relates to pharmaceutical compositions that are abuse resistant and may also provide controlled release. The present disclosure also relates to the use of pharmaceutical compositions in the treatment of pain.
    Type: Application
    Filed: April 10, 2014
    Publication date: August 7, 2014
    Applicant: EGALET LTD.
    Inventors: Peter Holm Tygesen, Karsten Lindhardt, Martin Rex Olsen, Gina Engslev Fischer, Jan Martin Overgard, Georg Boye, Nikolaj Skak, Torben Elhauge
  • Tamper Resistant Pharmaceutical Formulations
    Publication number: 20140221416
    Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse.
    Type: Application
    Filed: February 4, 2014
    Publication date: August 7, 2014
    Applicant: Purdue Pharma L.P.
    Inventors: Debora Guido, Haiyong Hugh Huang
  • Method of Treating Dyskinesia
    Publication number: 20140221415
    Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action mu-opioid receptor antagonist/kappa-opioid receptor agonist or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a mu-opioid receptor antagonist or prodrug thereof, and a kappa-opioid receptor agonist or prodrug thereof can be administered, either together or separately.
    Type: Application
    Filed: April 26, 2012
    Publication date: August 7, 2014
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: M. Maral Mouradian, Steven Braithwaite, Michael Voronkov
  • USE OF OPIOID ANTAGONISTS FOR TREATING URINARY RETENTION
    Publication number: 20140220146
    Abstract: The invention pertains to the use of opiod antagonists for the treatment of urinary retention.
    Type: Application
    Filed: April 10, 2014
    Publication date: August 7, 2014
    Applicant: Euro-Celtique S.A.
    Inventors: Michael HOPP, Petra LEYENDECKER
  • Methods related to the treatment of neurodegenerative and inflammatory conditions
    Patent number: 8796302
    Abstract: The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and/or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of the invention that include: valproic acid, sodium butyrate, and salts thereof; opioid peptides; a peptide comprising the tripeptide GGF; and morphinans, such as naloxone, naltrexone, 3-hydroxy-morphinan and dextromethorphan.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: August 5, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Jau-Shyong Hong, Liya Qin, Guorong Li, Michelle Block, Wei Zhang, Po-See Chen, Giia-Shuen Peng
  • Therapeutic or prophylactic agent for dyskinesia
    Patent number: 8796301
    Abstract: An object of the present invention is to provide a drug with a high therapeutic or prophylactic effect on dyskinesia, without accompanying aggravation of symptoms of the primary disease, and with fewer side effects. Accordingly, the present invention provides a therapeutic or prophylactic agent for dyskinesia, comprising as an effective component a compound having a 4,5-epoxy morphinan skeleton, which compound is represented by the Formula (I) below, or a pharmaceutically acceptable acid addition salt thereof: [wherein the double line composed of a dashed line and a solid line represents a double bond or single bond, R1 is C4-C7 cycloalkylalkyl, R2 is C1-C5 straight or branched alkyl, and B is —CH?CH—.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: August 5, 2014
    Assignee: Toray Industries, Inc.
    Inventors: Ken Ikeda, Hidenori Mochizuki
  • NEW ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE
    Publication number: 20140212496
    Abstract: There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.
    Type: Application
    Filed: September 18, 2012
    Publication date: July 31, 2014
    Applicant: OREXO AB
    Inventor: Andreas Fischer
  • METHODS FOR TREATING EYE DISORDERS USING OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20140213605
    Abstract: The present invention discloses methods for treating eye disorders using opioid receptor antagonists. The methods include the step of administering an effective amount of a topically-administered opioid receptor antagonist in the absence of moxifloxacin. Preferably, the topically-administered opioid receptor antagonist is formulated as a solution. Preferably, the topically-administered opioid receptor antagonist is at least one agent selected from the group consisting of: naltrexone, naloxone, nalmefene, and a pharmaceutically-acceptable salt thereof. Preferably, the effective amount corresponds to a concentration of at least about 10?7 molarity. Preferably, the effective amount is based on a treatment administration of at least once every other day.
    Type: Application
    Filed: March 11, 2013
    Publication date: July 31, 2014
    Applicant: Remedeye Inc.
    Inventor: Moshe Rogosnitzky
  • Pharmaceutical Formulation Containing Gelling Agent
    Publication number: 20140213606
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: April 2, 2014
    Publication date: July 31, 2014
    Applicants: Purdue Pharma L.P., Purdue Pharmaceuticals L.P., The P.F. Laboratories, Inc.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Tamper resistant transdermal dosage form
    Patent number: 8790689
    Abstract: The invention comprises a transdermal dosage form comprising an active agent component comprising an active agent and an adverse agent component comprising an adverse agent, wherein the active agent component defines at least one channel extending substantially there through.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: July 29, 2014
    Assignee: Purdue Pharma L.P.
    Inventors: Stephen A. Howard, Bruce Reidenberg
  • Gastric retentive extended release pharmaceutical compositions
    Patent number: 8790694
    Abstract: The present disclosure provides extended release pharmaceutical compositions comprising an opioid and an additional active pharmaceutical ingredient, wherein the composition exhibits gastric retentive properties which are achieved by a combination of a physical property of the composition and release of the opioid, wherein upon administration to a subject, the composition has at least one pharmacokinetic parameter that differs by less than about 30% when the subject is in a fasted state as compared to a fed state.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: July 29, 2014
    Assignee: Mallinckrodt LLC
    Inventors: Krishna R. Devarakonda, Michael J. Giuliani, Vishal K. Gupta, Ralph A. Heasley, Susan Shelby
  • OLIGOMER-OPIOID AGONIST CONJUGATES
    Publication number: 20140200235
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Application
    Filed: September 20, 2013
    Publication date: July 17, 2014
    Applicant: NEKTAR THERAPEUTICS
    Inventors: Jennifer RIGGS-SAUTHIER, Bo-Liang Deng, Timothy A. Riley
  • OPIOID AGONIST/ANTAGONIST COMBINATIONS
    Publication number: 20140200236
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Application
    Filed: March 14, 2014
    Publication date: July 17, 2014
    Applicant: PURDUE PHARMA L.P.
    Inventors: Robert F. KAIKO, Robert D. Colucci
  • CONTROLLED RELEASE HYDROCODONE
    Publication number: 20140199394
    Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.
    Type: Application
    Filed: March 14, 2014
    Publication date: July 17, 2014
    Applicant: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Hua-Pin HUANG, John K. Masselink, Alfred Tonelli
  • Synthesis of metabolically stable agents for alcohol and drug abuse
    Patent number: 8778958
    Abstract: The disclosed opioid-related compounds and pharmaceutical compositions thereof, are useful in a variety of applications relating to the modulation of receptors and receptor signaling within and outside the nervous system. For example, the compounds and compositions are useful in methods for the treatment of addictions and other CNS-related disorders. The disclosed compounds can be delivered or administered to a mammal including humans, alone in the form of a pharmaceutically acceptable salt or hydrolysable precursor thereof, or in the form of a pharmaceutical composition, wherein a therapeutically effective amount of a compound is mixed with suitable carriers or excipients.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: July 15, 2014
    Inventor: John R. Cashman
  • ABUSE-RESISTANT CONTROLLED-RELEASE OPIOID DOSAGE FORM
    Publication number: 20140194456
    Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.
    Type: Application
    Filed: March 11, 2014
    Publication date: July 10, 2014
    Applicant: Purdue Pharma
    Inventors: Frank S. CARUSO, Huai-Hung KAO
  • ORAL DOSAGE FORMS WITH THERAPEUTICALLY ACTIVE AGENTS IN CONTROLLED RELEASE CORES AND IMMEDIATE RELEASE GELATIN CAPSULE COATS
    Publication number: 20140193490
    Abstract: The present invention relates to oral dosage form with active agents in controlled release cores and in immediate release gelatin capsule coats.
    Type: Application
    Filed: July 24, 2013
    Publication date: July 10, 2014
    Applicant: Pain Therapeutics, Inc.
    Inventor: Grant L. Schoenhard
  • CARBOXAMIDE BIOISOSTERES OF OPIATES
    Publication number: 20140194457
    Abstract: A compound of formula I is disclosed. Compounds of formula I are useful as analgesics, anti-inflammatory agents, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.
    Type: Application
    Filed: March 12, 2014
    Publication date: July 10, 2014
    Applicant: Rensselaer Polytechnic Institute
    Inventor: Mark P. WENTLAND
  • OXIDATION-STABILIZED TAMPER-RESISTANT DOSAGE FORM
    Publication number: 20140194455
    Abstract: A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.
    Type: Application
    Filed: February 28, 2014
    Publication date: July 10, 2014
    Applicant: GRUNENTHAL GMBH
    Inventors: Lutz BARNSCHEID, Eric GALIA, Sebastian SCHWIER, Ulrike BERTRAM, Anja GEISSLER, Kornelia GRIESSMANN, Johannes BARTHOLOMÄUS
  • Sustained release formulations of nalbuphine
    Patent number: 8771732
    Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: July 8, 2014
    Assignee: Endo Pharmaceuticals Inc
    Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler
  • Non-peptidyl, potent, and selective mu opioid receptor antagonists
    Patent number: 8772308
    Abstract: Selective, non-peptide antagonists of the mu opioid receptor (MOR) and methods of their use are provided. The antagonists may be used, for example, to identify MOR agonists in competitive binding assays, and to treat conditions related to addiction in which MOR is involved, e.g. heroin, prescription drug and alcohol addiction.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: July 8, 2014
    Assignee: Virginia Commonwealth University
    Inventors: Yan Zhang, Dana E. Selley, William Dewey
  • Transdermal Pharmaceutical Delivery Composition
    Publication number: 20140187481
    Abstract: A pharmaceutically delivery system is described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent.
    Type: Application
    Filed: July 3, 2013
    Publication date: July 3, 2014
    Inventors: Arthur Tudor Tucker, Nigel Benjamin
  • GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF A NON-OPIOID ANALGESIC AND AN OPIOID ANALGESIC
    Publication number: 20140186440
    Abstract: Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.
    Type: Application
    Filed: March 4, 2014
    Publication date: July 3, 2014
    Applicant: Depomed, Inc.
    Inventors: Chien-Hsuan Han, Sui Yuen Eddie Hou, Monica L. Reid
  • OPIOID DOSAGE FORMS HAVING DOSE PROPORTIONAL STEADY STATE CAVE AND AUC AND LESS THAN DOSE PROPORTIONAL SINGLE DOSE CMAX
    Publication number: 20140187572
    Abstract: The present invention relates to a plurality of dosage forms comprising a first dosage form and second dosage form each comprising a therapeutic agent, such as an opioid; wherein the dosage strength of the second dosage form is greater than that of the first dosage form; and wherein the steady state Cave and the steady state AUC of the first and second dosage forms are dose proportional and the single dose Cmax of the second dosage form is less than the minimum level for dose proportionality with respect to the first dosage form. The present invention also relates to methods of administering such dosage forms to a patient, as well as to kits comprising such dosage forms and instructions for administration of the dosage forms to a patient. The inventors believe that the dosage forms and methods of the present invention will lead to improved safety and patient acceptance.
    Type: Application
    Filed: March 7, 2014
    Publication date: July 3, 2014
    Applicant: Purdue Pharma L.P.
    Inventors: Curtis Wright, Robert Colucci, Ahmed El-Tahtawy
  • ORAL DOSAGE FORMS WITH THERAPEUTICALLY ACTIVE AGENTS IN CONTROLLED RELEASE CORES AND IMMEDIATE RELEASE GELATIN CAPSULE COATS
    Publication number: 20140186437
    Abstract: The present invention relates to oral dosage form with active agents in controlled release cores and in immediate release gelatin capsule coats.
    Type: Application
    Filed: March 7, 2014
    Publication date: July 3, 2014
    Applicant: Pain Therapeutics, Inc.
    Inventor: Grant L. Schoenhard
  • Controlled release formulations and associated methods
    Patent number: 8765178
    Abstract: A pharmaceutical formulation having a geometric configuration that affects the release characteristics of active agents contained therein and associated methods are provided. In one aspect, a sustained release oral dosage pharmaceutical tablet may include a first layer having a first active agent, where the first layer is disposed between two adjacent controlled release layers, at least one of the adjacent layers including at least one second active agent. The two adjacent layers are arranged such that they cover a portion of the first layer. The two adjacent layers may be separate layers or they may be joined into a single continuous layer, depending on the overall configuration and geometric design of the oral dosage form.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: July 1, 2014
    Assignee: Watson Laboratories, Inc.
    Inventors: Nilesh H. Parikh, Teshome Melaku
  • Sustained release formulation of nalbuphine
    Patent number: 8765175
    Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: July 1, 2014
    Assignee: Endo Pharmaceuticals Inc
    Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler, David Verbel, Stanley Au
  • COMPOSITIONS FOR TREATING CMT AND RELATED DISORDERS
    Publication number: 20140178463
    Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 26, 2014
    Inventors: DANIEL COHEN, SERGUEI NABIROCHKIN, ILYA CHUMAKOV
  • ORAL DOSAGE FORMS FOR OXYGEN-CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMER
    Publication number: 20140179729
    Abstract: The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts. In one embodiment, a pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The total oxyl content of the hydrophilic polymer in the tablet is about 4×10?4 moles to about 2.0×10?3 moles.
    Type: Application
    Filed: February 28, 2014
    Publication date: June 26, 2014
    Applicant: Spriaso LLC
    Inventors: Chandrashekar Giliyar, Satish Kumar Nachaegari, Chidambaram Nachiappan, Mahesh V. Patel, Srinivansan Venkateshwaran